Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia

Core Viewpoint - Karolinska Development AB's portfolio company, Modus Therapeutics, has initiated the second part of a phase 2a clinical study for sevuparin, targeting chronic kidney disease with anemia, following a successful first part that demonstrated safety and provided insights for dose selection [1][2][4]. Group 1: Clinical Study Details - The second part of the phase 2a study will focus on repeated dosing of sevuparin, assessing safety and clinically relevant efficacy outcomes, including hemoglobin and hepcidin levels, along with other kidney- and blood-related biomarkers [3]. - A total of 50 to 60 patients will be enrolled in this study [3]. Group 2: Company Background and Ownership - Karolinska Development holds a 54% direct and 1% indirect ownership stake in Modus Therapeutics [4]. - The company is a Nordic life sciences investment firm that seeks to identify and develop breakthrough medical innovations, aiming to create and grow companies that can deliver impactful medical products [5][6]. Group 3: Strategic Focus - Karolinska Development collaborates with leading universities and research institutes in the Nordic region to access world-class medical innovations, focusing on building companies around top scientists supported by experienced management teams [6]. - The company has a portfolio of eleven companies that target innovative treatments for serious diseases, led by a team of investment professionals with a strong track record [7].